Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Nevis Brands Inc C.NEVI

Alternate Symbol(s):  NEVIF

Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include the flagship brand Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent cannabis experience with no cannabis taste or smell. Major offers various flavors, such as volcanic orange mango, sunset pink lemonade, Pacific Coast blue raspberry, dreamin' of passion, and sacred grape. It also offers Major Minis, which is a smaller 2 ounce (oz) shot. Major Minis come in three flavors, such as blueberry, fruit punch, and blackberry lemonade. The Company has introduced Major Mojo-Rita and Sugar-Free Ginger-ade in Washington and Major Sugar-Free Lemonade and Apple Peach in Missouri.


CSE:NEVI - Post by User

Post by Traderstock101on Oct 29, 2021 8:37am
225 Views
Post# 34062308

Pascal Biosciences arranges $900,000 private placement 0.10¢

Pascal Biosciences arranges $900,000 private placement 0.10¢

2021-10-28 09:05 ET - News Release

Dr. Patrick Gray reports

PASCAL BIOSCIENCES ANNOUNCES FINANCING

Pascal Biosciences Inc. has provided an update on the development of the company's PAS-403 and PAS-393 patented molecules for development of cancer therapeutics prior to commencing clinical trials and for general working capital to support this direction.

The company has arranged a non-brokered private placement financing of up to nine million units of securities at a price of 10 cents per unit for aggregate gross proceeds of up to $900,000. Each unit will comprise one common share and one non-transferable common share purchase warrant, with each whole warrant entitling the holder to purchase one additional common share at a price of 15 cents for two years from the closing date of the private placement. The exercise term of the warrant will be accelerated in the event the closing price of the shares is above 20 cents for 10 consecutive days and will be exercisable for a period of 15 days from the date of receipt by investors of a notice of acceleration. Finder's fees of up to 10 per cent may be paid.

All securities issued will be subject to a four-month holding period which will expire on the date that is four months and one day from the date of issue.

About Pascal Biosciences Inc.

Pascal is a biotechnology company advancing innovative therapies for serious diseases. In addition to a targeted therapy for acute lymphoblastic leukemia, Pascal is developing cannabinoid-based treatments for cancer. These compounds include PAS-403, which is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy to treat multiple cancers. The PAS-393 program is being developed collaboratively with SoRSE Technology.

<< Previous
Bullboard Posts
Next >>